68Ga-DOTA-E-[c(RGDfK)]2 PET/CT 在尼达尼布联合多西他赛治疗的肺腺癌患者中的疗效评估
研究纳入38例接受二线尼达尼布联合多西他赛治疗的肺腺癌患者,于治疗2周期前后行68Ga-DOTA-E-[c(RGDfK)]2 PET/CT及血管生成因子血样检测。31例有可评估的基线与随访PET/CT。基线与血清血管内皮生长因子及血小板衍生生长因子AB相关,肿瘤体积下降幅度更大者疾病控制率更好(P=0.005),肺SUVmax下降更大者总生存更长(P=0.016)。
要点
- 基线肺肿瘤体积与血清血管内皮生长因子水平相关,基线肺/肝SUVmax指数与血小板衍生生长因子AB相关。
- 肺肿瘤体积下降-37.2% vs -27.6%与更好的疾病控制率相关(P=0.005)。
- 肺SUVmax下降更大者总生存更长(未达到 vs 7.1个月,P=0.016)。
核心结论
- 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT是评估血管生成抑制剂疗效的潜在有用工具。
- 原文结论指出需进一步分析和新的研究以识别可能从该治疗中获益的患者。
研究设计与样本
- 研究于2011年7月至2015年10月纳入38例接受二线尼达尼布联合多西他赛治疗的肺腺癌患者。
- 所有患者于完成2个治疗周期前后行68Ga-DOTA-E-[c(RGDfK)]2 PET/CT及血样检测以量化血管生成因子(成纤维细胞生长因子、血管内皮生长因子、血小板衍生生长因子AB)。
- 38例中31例有可用的基线与随访PET/CT。
主要发现
- 治疗后总体缓解率为7.9%,疾病控制率为47.3%。
- 肺肿瘤体积下降-37.2% vs -27.6%与更好的疾病控制率相关(P=0.005)。
- 中位无进展生存期为3.7个月。
- 不吸烟者与基线肺肿瘤体积较高的患者更可能有更高的无进展生存期(6.4 vs 3.74个月,P=0.023;6.4 vs 2.1个月,P=0.003)。
- 总生存未达到;肺SUVmax下降更大者(未达到 vs 7.1个月,P=0.016)和肺/脾SUVmax指数下降更大者(未达到 vs 7.1个月,P=0.043)更可能有更长的总生存。
关键数值与推荐
- 基线肺肿瘤体积与血清血管内皮生长因子水平相关。
- 基线肺/肝SUVmax指数与血小板衍生生长因子AB相关。
- 治疗后总体缓解率为7.9%,疾病控制率为47.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步分析和新的研究以识别可能从该治疗中获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nintedanib is an oral angiokinase inhibitor used as second-line treatment for non-small cell lung cancer. New radiotracers, such as 68Ga-DOTA-E-[c(RGDfK)]2, that target αvβ3 integrin might have an impact as a noninvasive method for assessing angiogenesis inhibitors. Methods: From July 2011 through October 2015, 38 patients received second-line nintedanib plus docetaxel. All patients underwent PET/CT with 68Ga-DOTA-E-[c(RGDfK)]2 radiotracer and blood-sample tests to quantify angiogenesis factors (fibroblast growth factor, vascular endothelial growth factor, and platelet-derived growth factor AB) before and after completing 2 therapy cycles. Results: Of the 38 patients, 31 had available baseline and follow-up PET/CT. Baseline lung tumor volume addressed with 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT correlated with serum vascular endothelial growth factor levels, whereas baseline lung/liver SUVmax index correlated with platelet-derived growth factor AB. After treatment, the overall response rate and disease control rate were 7.9% and 47.3%, respectively. A greater decrease in lung tumor volume (-37.2% vs. -27.6%) was associated with a better disease control rate in patients (P = 0.005). Median progression-free survival was 3.7 mo. Nonsmokers and patients with a higher baseline lung tumor volume were more likely to have a higher progression-free survival (6.4 vs. 3.74 [P = 0.023] and 6.4 vs. 2.1 [P = 0.003], respectively). Overall survival was not reached. Patients with a greater decrease in lung SUVmax (not reached vs. 7.1 mo; P = 0.016) and a greater decrease in the lung/spleen SUVmax index (not reached vs. 7.1; P = 0.043) were more likely to have a longer overall survival. Conclusion:68Ga-DOTA-E-[c(RGDfK)]2 PET/CT is a potentially useful tool for assessing responses to angiogenesis inhibitors. Further analysis and novel studies are warranted to identify patients who might benefit from this therapy.
引用
- Arrieta O, Garcia-Perez FO, Michel-Tello D, et al. Response Assessment of 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel. J Nucl Med. 2017. PMID: 28818987. doi:10.2967/jnumed.117.192393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。